A liquid matrix-assisted
laser desorption/ionization (liquid MALDI)
method has been developed for high-throughput atmospheric pressure
(AP) mass spectrometry (MS) analysis of the molecular content of crude
bioliquids for disease diagnostics. The presented method is rapid
and highly robust, enabling its application in environments where
speed and low-cost high-throughput analyses are required. Importantly,
because of the creation of multiply charged analyte ions, it provides
additional functionalities that conventional solid MALDI MS profiling
is lacking, including the use of high-performance mass analyzers with
limited
m
/
z
range. The concomitant
superior MS/MS performance that is achieved similar to ESI MS/MS adds
greater analytical power and specificity to MALDI MS profiling while
retaining the advantages of a fast laser-based analysis system and
off-line large-scale sample preparation. The potential of this MALDI
MS profiling method is demonstrated on the detection of dairy cow
mastitis, which is a substantial economic burden on the dairy industry
with losses of hundreds of dollars per diseased cow per year, equating
to a total annual loss of billions of dollars, as well as leading
to the use of large quantities of antibiotics, adding to the proliferation
of antimicrobial resistance. Only small amounts of aliquots obtained
from the daily farm milking process were prepared for liquid MALDI
MS profiling using a simple one-pot/two-step analyte extraction. Automated
analysis was performed using a custom-built AP-MALDI ion source, enabling
the simultaneous detection of lipids, peptides, and proteins. Diagnostic,
multiply charged, proteinaceous ions were easily sequenced and identified
by MS/MS experiments. Samples were classified according to mastitis
status using multivariate analysis, achieving 98.5% accuracy (100%
specificity) determined by “leave 20% out” cross-validation.
The methodology is generally applicable to AP-MALDI MS profiling on
most commercial high-resolution mass spectrometers, with the potential
for expansion into hospitals for rapid assessment of human and other
biofluids.